At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum
University Hospitals Cleveland Medical Center·interventional·Posted Nov 14, 2008·Updated Nov 2, 2016
In Brief
A clinical study evaluating Infliximab for Pyoderma Gangrenosum and 3 related conditions. Completed, enrolled 2 participants across 1 site.
Detailed Summary
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCentocor, Inc.
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedNov 2008
Primary CompletionDec 2009
Study CompletionFeb 2010
TodayJul 2026
First PostedNov 14, 2008
Enrollment StartOct 1, 2008
Primary CompletionDec 1, 2009
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.6 years ago
Interventions
Infliximabdrug
IV drug given at weeks 1,2,14,22